Pulmonary Neuroendocrine Tumors: What (Little) Do We Know?

By Chen Lin-Chi   Travis William D.   Krug Lee M.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 6, 2006-07 ,pp. : 623-630

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Idarucizumab: What Should We Know?

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

By Jones Drew R   Miller Grover P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 857-874

Informa Healthcare

Access to resources Recommend Favorite

What we know and what we think we know: An editor's perspective on a charged debate

By Khuri Fadlo R.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 4-5

Blackwell Publishing

Access to resources Recommend Favorite

Rosiglitazone and MI risk - will we ever know the answer?

By  

Reactions Weekly, Vol. 1, Iss. 1158, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite